ESR1 and glaucoma: Given the evidence that RGCs express estrogen receptors, lower estradiol levels are linked with primary open-angle glaucoma (POAG) [26], and that β-estradiol can protect from RGC death [23,27,28], an estrogen analogue-based therapy may be of benefit in many glaucoma patients.